NOXOPHARM LIMITED

NOX
End-of-day quote. End-of-day quote  - 10/22
0.535AUD +0.94%

Noxopharm Announces Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

08/26/2021 | 08:00am
Noxopharm has reported preclinical data that further supports the role of experimental anti-cancer drug, idronoxil, the active ingredient in Veyonda, as an anti-inflammatory drug for early-stage COVID-19 treatments. A recent preclinical trial, conducted in partnership with Australia’s Hudson Institute of Medical Research (Hudson Institute), has identified that idronoxil inhibits the enzyme, TANK-binding kinase 1 (TBK1), an action that potentially dampens the inflammatory response causing the progression of COVID-19 disease from mild-to-severe, but not compromising the body’s ability to fight the virus. These preclinical findings support preliminary top-line positive results the company shared earlier from its NOXCOVID Phase I clinical trial, which tested the suitability of idronoxil (Veyonda) as an effective anti-inflammatory in patients hospitalized with moderate COVID-19 disease. One particular relevance of TBK1 as a drug target is its role in responding to infections from RNA viruses including the respiratory RNA viruses - coronaviruses, influenza virus and respiratory syncytial virus.
© S&P Capital IQ 2021
Copier lien
All news about NOXOPHARM LIMITED
09/27
09/26
09/20
08/29
08/26